AveXis Inc. (NASDAQ:AVXS) shares saw unusually-high trading volume on Thursday . Approximately 284,492 shares changed hands during trading, an increase of 39% from the previous session’s volume of 204,773 shares.The stock last traded at $34.83 and had previously closed at $36.07.

AVXS has been the topic of several research reports. Chardan Capital initiated coverage on shares of AveXis in a research report on Monday, March 28th. They set a “buy” rating and a $60.00 price target on the stock. Zacks Investment Research upgraded shares of AveXis from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Thursday, May 12th. Goldman Sachs Group Inc. upped their price target on shares of AveXis from $28.00 to $47.00 and gave the stock a “buy” rating in a research report on Friday, May 13th. Finally, Jefferies Group downgraded shares of AveXis from a “buy” rating to a “hold” rating and upped their price target for the stock from $39.00 to $42.00 in a research report on Wednesday, June 22nd. They noted that the move was a valuation call. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $43.80.

The stock’s 50-day moving average price is $40.88 and its 200-day moving average price is $30.41. The firm’s market cap is $811.44 million.

AveXis (NASDAQ:AVXS) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($1.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.89. Analysts anticipate that AveXis Inc. will post ($4.00) earnings per share for the current year.

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.